Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-escalation study of bevacizumab-IRDye800CW for fluorescence-guided breast cancer surgery
NL-OMON42239Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Tumor to background ratio. Started Oct 2015; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON42239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42239.